Next Article in Journal
Low Plasma Sphingomyelin Levels Show a Weak Association with Poor Neurological Outcome in Cardiac Arrest Patients: Results from the Prospective, Observational COMMUNICATE Trial
Next Article in Special Issue
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
Previous Article in Journal
Unmet Medical Needs of Patients with Benign Prostate Enlargement
Previous Article in Special Issue
Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 4
10.3390/jcm9040896
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?

by
Robin Kikuchi
1,
Nishant P. Shah
2 and
Susan F. Dent
1,*
1
Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA
2
Division of Cardiology, Duke Heart Center, Duke University, Durham, NC 27710, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 896; https://doi.org/10.3390/jcm9040896
Submission received: 26 February 2020 / Revised: 16 March 2020 / Accepted: 20 March 2020 / Published: 25 March 2020
(This article belongs to the Special Issue Early Diagnosis, Monitoring, Prevention and Treatment of Cardiotoxicity)
Browse Figure
Versions Notes

Abstract

Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exposed to these agents. Novel cancer therapies have led to significant improvements in clinical outcomes for breast cancer patients. In this article, we review the current literature on assessing cardiovascular risk of breast cancer therapies and discuss strategies (including pharmacological and lifestyle interventions) to prevent cardiovascular toxicity.
Keywords: Cardio-oncology; cardiotoxicity; oncology; cardiology; primary prevention; breast cancer; anthracyclines; trastuzumab Cardio-oncology; cardiotoxicity; oncology; cardiology; primary prevention; breast cancer; anthracyclines; trastuzumab
Graphical Abstract

Share and Cite

MDPI and ACS Style

Kikuchi, R.; Shah, N.P.; Dent, S.F. Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? J. Clin. Med. 2020, 9, 896. https://doi.org/10.3390/jcm9040896

AMA Style

Kikuchi R, Shah NP, Dent SF. Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? Journal of Clinical Medicine. 2020; 9(4):896. https://doi.org/10.3390/jcm9040896

Chicago/Turabian Style

Kikuchi, Robin, Nishant P. Shah, and Susan F. Dent. 2020. "Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?" Journal of Clinical Medicine 9, no. 4: 896. https://doi.org/10.3390/jcm9040896

APA Style

Kikuchi, R., Shah, N. P., & Dent, S. F. (2020). Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime? Journal of Clinical Medicine, 9(4), 896. https://doi.org/10.3390/jcm9040896

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop